Last checked at 1 Oct 2013 07:00
Director / PDMR Shareholding
Phytopharm PLC
("the Company" or "Phytopharm")
1 October 2013
Director's dealings
The Company today announces that it was notified on 30 September 2013 that, on the same day, Charles Spicer, Vice President of Corporate Development of IXICO Limited ("IXICO"), purchased 33,082 Ordinary Shares of 50p each in Phytopharm at a price of 60 pence per Ordinary Share.
On 23 September 2013, Phytopharm announced that terms had been agreed for the conditional acquisition of IXICO. The acquisition of IXICO is classified as a reverse takeover under the AIM Rules and is therefore conditional, inter alia, on the approval of Shareholders in a general meeting.
As a consequence of this share purchase, Charles Spicer, a proposed Director of Phytopharm (to be renamed IXICO plc upon completion), has a total holding of 33,082 Ordinary Shares, representing 0.48% of Phytopharm's issued share capital. Following completion, Charles Spicer's beneficial interest in the Company is expected to be 33,082 Ordinary Shares, representing 0.22% of the Company's enlarged issued share capital.
Enquiries
Phytopharm plc
Tim Sharpington, CEO
+44 1480 437 697
Peel Hunt LLP (Nominated Adviser and Broker)
James Steel
Vijay Barathan
+44 207 418 8900
Investor Relations
FTI Consulting Limited
Ben Atwell
Simon Conway
John Dineen
+44 207 831 3113